Subscribe

News
Watch
Conferences
Partners
CME/CE
Resources
Advisory Board
Subscribe

Spotlight -

This Year In Medicine 2025

Opinion|Videos|December 16, 2024

Primary Treatment Goals for Patients With IgAN

Author(s)Jonathan Barratt, PhD, FRCP, Anuja Java, MD, Brendon Neuen, MBBS, PhD

Key Takeaways

Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Clinical indicators like tumor size, stage, and overall health status are crucial in assessing disease outcomes.
Personalized medicine utilizes biomarkers to customize treatment plans, improving therapeutic efficacy and patient survival.

SHOW MORE

Panelists discuss how the primary treatment goals for patients with IgA nephropathy evolve based on the stage of the disease, emphasizing the importance of tailoring strategies to individual patient needs.

Episodes in this series

EP. 1 Overview of IgAN and Its Common Symptoms

EP. 1 Overview of IgAN and Its Common Symptoms

EP. 2 IgAN Progression

EP. 2 IgAN Progression

EP. 3 IgAN vs Other Glomerular Diseases

EP. 3 IgAN vs Other Glomerular Diseases

EP. 4 Biomarkers for IgAN

EP. 4 Biomarkers for IgAN

EP. 5 Genetic Screening for IgAN

EP. 5 Genetic Screening for IgAN

EP. 6 Impact of IgAN on Quality of Life

EP. 6 Impact of IgAN on Quality of Life

EP. 7 Misdiagnosis and Barriers to Early Detection of IgAN

EP. 7 Misdiagnosis and Barriers to Early Detection of IgAN

EP. 8 Differential Diagnoses of IgAN

EP. 8 Differential Diagnoses of IgAN

EP. 9 Significance of Proteinuria for Potential IgAN

EP. 9 Significance of Proteinuria for Potential IgAN

EP. 10 Proteinuria Variability and IgAN Diagnosis

EP. 10 Proteinuria Variability and IgAN Diagnosis

EP. 11 Biomarkers and Improving IgAN Diagnostic Accuracy

EP. 11 Biomarkers and Improving IgAN Diagnostic Accuracy

EP. 12 Primary Treatment Goals for Patients With IgAN

EP. 12 Primary Treatment Goals for Patients With IgAN

EP. 13 Proteinuria Reduction in Long-Term Kidney Damage Prevention

EP. 13 Proteinuria Reduction in Long-Term Kidney Damage Prevention

EP. 14 Symptoms Management and Targeting the Root Cause of IgAN

EP. 14 Symptoms Management and Targeting the Root Cause of IgAN

EP. 15 Unmet Needs in Current IgAN Treatment

EP. 15 Unmet Needs in Current IgAN Treatment

EP. 16 Prospective Improvements of Existing IgAN Therapies

EP. 16 Prospective Improvements of Existing IgAN Therapies

EP. 17 Safety of IgAN Treatments

EP. 17 Safety of IgAN Treatments

EP. 18 The Promise of Emerging IgAN Therapies

EP. 18 The Promise of Emerging IgAN Therapies

EP. 19 Emerging Therapies: a look at the current data: ALIGN

EP. 19 Emerging Therapies: a look at the current data: ALIGN

EP. 20 Emerging Therapies: a look at the current data: APPLAUSE

EP. 20 Emerging Therapies: a look at the current data: APPLAUSE

EP. 21 Emerging Therapies: a look at the current data: PROTECT study

EP. 21 Emerging Therapies: a look at the current data: PROTECT study

EP. 22 Emerging Therapies: a look at the current data: NefIgArd study

EP. 22 Emerging Therapies: a look at the current data: NefIgArd study

EP. 23 Implementing New IgAN Therapies Into Clinical Practice

EP. 23 Implementing New IgAN Therapies Into Clinical Practice

EP. 24 Shared Decision-Making for IgAN Treatment

EP. 24 Shared Decision-Making for IgAN Treatment

EP. 25 Summary and Closing Remarks

EP. 25 Summary and Closing Remarks

What are the primary treatment goals for patients with IgA nephropathy, and how do they evolve based on the stage of the disease?

Newsletter

Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.

Latest CME

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2)

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2)

Suneel Udani, MD

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

Jean M. Elwing, MD, FCCP; Russel Hirsch, MD; John F. Morehous, MD

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

Jean M. Elwing, MD, FCCP; Russel Hirsch, MD; John F. Morehous, MD

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

Jean M. Elwing, MD, FCCP; Russel Hirsch, MD; John F. Morehous, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Edgar V. Lerma, MD; Anuradha Lala-Trindade, MD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Jennifer Green, MD; Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

2026 International Symposium of Gastrointestinal Oncology (ISGIO)

In-Person Event

2026 International Symposium of Gastrointestinal Oncology (ISGIO)

October 2-3, 2026

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

IgAN Case Files: Real Conversations, Evolving Evidence

IgAN Case Files: Real Conversations, Evolving Evidence

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Elizabeth Burgener, MD; Leah A. Cohen, MD; William R. Hunt, MD, FAAP, FACP, FSSCI

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Elizabeth Burgener, MD; Leah A. Cohen, MD; William R. Hunt, MD, FAAP, FACP, FSSCI

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Elizabeth Burgener, MD; Leah A. Cohen, MD; William R. Hunt, MD, FAAP, FACP, FSSCI

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Case-based Simulation

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Jae Park, MD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Targeting the Cortisol Cascade: Diagnosis and Treatment Strategies in Patients with Hypertension

Targeting the Cortisol Cascade: Diagnosis and Treatment Strategies in Patients with Hypertension

Hanford Yau, MD; Stephen J. Greene, MD

Targeting the Cortisol Cascade: Diagnosis and Treatment Strategies in Patients with Hypertension

Targeting the Cortisol Cascade: Diagnosis and Treatment Strategies in Patients with Hypertension

Hanford Yau, MD; Stephen J. Greene, MD

Patient, Provider, and Caregiver Connection™: Individualizing Care in C3 Glomerulopathy – Understanding Patient Challenges and the Role of Innovative Treatment

Patient, Provider, and Caregiver Connection™: Individualizing Care in C3 Glomerulopathy – Understanding Patient Challenges and the Role of Innovative Treatment

Jonathan Barratt, PhD, FRCP; Brendon L. Neuen, MBBS, PhD, MSc

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Geoffery Ku, MD; Shruti Patel, MD

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

Screening for Type 1 Diabetes and Delaying Its Onset—An Innovative View

Screening for Type 1 Diabetes and Delaying Its Onset—An Innovative View

Jennifer D. Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP; Robert Busch, MD; Conan Tu, MD, MBA, DACD, BC-ADM; Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Deep Parikh, MD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Dilsher S. Dhoot, MD, FASRS

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Burst CME™: Optimal Management of Complications of Sickle Cell Disease

Burst CME™: Optimal Management of Complications of Sickle Cell Disease

Matthew Heeney, MD; Deepika S, Darbari, MD

Burst CME™: Optimal Management of Complications of Sickle Cell Disease

Burst CME™: Optimal Management of Complications of Sickle Cell Disease

Matthew Heeney, MD; Deepika S, Darbari, MD

Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease

Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease

Biree Andemariam, MD; Nirmish Shah, MD

Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease

Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease

Biree Andemariam, MD; Nirmish Shah, MD

Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?

Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?

Matthew Heeney, MD; Biree Andemariam, MD

Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?

Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?

Matthew Heeney, MD; Biree Andemariam, MD

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Steven Fein, MD

Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification

Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification

Erin D. Michos, MD, MHS; Nihar Desai, MD, MPH

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

Jordan E. Axelrad, MD, MPH, FACG

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

Jordan E. Axelrad, MD, MPH, FACG

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Cases and Conversations™: Navigating CKD and Heart Failure in T1D and T2D—Applying the Latest Guidelines and Evidence

Cases and Conversations™: Navigating CKD and Heart Failure in T1D and T2D—Applying the Latest Guidelines and Evidence

Stephen J Greene, MD; Anuradha Lala-Trindade, MD

Advances in™: Lipoprotein(a) as a Target for ASCVD Risk Reduction – Updates for Clinical Practice

Advances in™: Lipoprotein(a) as a Target for ASCVD Risk Reduction – Updates for Clinical Practice

Pam R. Taub, MD, FACC, FASPC; Payal Kohli, MD, FACC

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

Burst CME™: Burden of Sickle Cell Disease

Burst CME™: Burden of Sickle Cell Disease

Matthew Heeney, MD; Biree Andemariam, MD

Burst CME™: Burden of Sickle Cell Disease

Burst CME™: Burden of Sickle Cell Disease

Matthew Heeney, MD; Biree Andemariam, MD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Rahul Gosain, MD, MBA; Rohit Gosain, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on HCPLive

VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes

Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study

New Liver Cancer BEACON-HCC Framework Shows 96.6% Concordance in Pilot

After Sickle Cell Gene Therapy, What Comes Next?

DPP1 Inhibition in Bronchiectasis: Mechanism and Pivotal Trial Data